Home treatment of haemarthrosis with recombinant activated factor VII in patients with haemophilia A or B and inhibitors: experience from developing countries

Meriem Bensadok, Abdulkareem Almomen, Azzam Alzoebie, Soraya Benchikh el Fegoun, Yasser Wali, Fati Hamzy, Nemra Gaid Mehalhal, Fatiha Grifi, Selma Hamdi, Naima Mesli, Tarek Owaidah, Hossam Ali Saad, Nouredine Sidi Mansour, Hadj Touhami

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Home therapy for uncomplicated mild/moderate bleeding can decrease healthcare burden, promote self-esteem, reduce complications, and provide near-normal quality of life. To evaluate recombinant activated factor VII (rFVIIa) as home therapy for joint bleeds in Algeria, Morocco, Oman, Saudi Arabia, and United Arab Emirates. Twenty-seven patients aged more than 2 years with congenital haemophilia and inhibitors were monitored for up to 8 months after a first haemarthrosis episode treated with rFVIIa. Assessments were made by patients/caregivers with a standardized diary. The main measures included home-managed bleeds, haemostasis, and pain relief within 9?h after first injection. Additional analyses included convenience, time to pain resolution, and doses given within 48?h. Of 132 bleeds, 84 (63.6%) were managed at home. Of these, successful haemostasis (partial or complete) was achieved at 9?h in 87.8%, with pain relief for 84.0%. For all treatment settings, successful haemostasis at 9?h was achieved for 86.3% of bleeds, with pain relief achieved for 74.8% of bleeds. Higher initial dosing was associated with fewer injections. Median time to complete haemostasis was 48?h (spontaneous bleeds) and 24?h (traumatic bleeds). Median time to complete pain relief was 24?h for both bleed types. Satisfaction with treatment was high. No safety concerns were reported. Results from this observational study agree with previous data on the safety and efficacy of home treatment with rFVIIa and will help to increase awareness and aggregate experience, fostering confidence in home management of haemophilia patients with inhibitors in developing countries.

Original languageEnglish
JournalBlood Coagulation and Fibrinolysis
DOIs
Publication statusAccepted/In press - Apr 20 2016

Fingerprint

Hemarthrosis
Hemophilia B
Factor VIIa
Hemophilia A
Developing Countries
Hemostasis
Pain
United Arab Emirates
Oman
Algeria
Therapeutics
Safety
Morocco
Injections
Foster Home Care
Saudi Arabia
Self Concept
Caregivers
Observational Studies
Joints

ASJC Scopus subject areas

  • Hematology

Cite this

Home treatment of haemarthrosis with recombinant activated factor VII in patients with haemophilia A or B and inhibitors : experience from developing countries. / Bensadok, Meriem; Almomen, Abdulkareem; Alzoebie, Azzam; el Fegoun, Soraya Benchikh; Wali, Yasser; Hamzy, Fati; Mehalhal, Nemra Gaid; Grifi, Fatiha; Hamdi, Selma; Mesli, Naima; Owaidah, Tarek; Saad, Hossam Ali; Mansour, Nouredine Sidi; Touhami, Hadj.

In: Blood Coagulation and Fibrinolysis, 20.04.2016.

Research output: Contribution to journalArticle

Bensadok, M, Almomen, A, Alzoebie, A, el Fegoun, SB, Wali, Y, Hamzy, F, Mehalhal, NG, Grifi, F, Hamdi, S, Mesli, N, Owaidah, T, Saad, HA, Mansour, NS & Touhami, H 2016, 'Home treatment of haemarthrosis with recombinant activated factor VII in patients with haemophilia A or B and inhibitors: experience from developing countries', Blood Coagulation and Fibrinolysis. https://doi.org/10.1097/MBC.0000000000000564
Bensadok, Meriem ; Almomen, Abdulkareem ; Alzoebie, Azzam ; el Fegoun, Soraya Benchikh ; Wali, Yasser ; Hamzy, Fati ; Mehalhal, Nemra Gaid ; Grifi, Fatiha ; Hamdi, Selma ; Mesli, Naima ; Owaidah, Tarek ; Saad, Hossam Ali ; Mansour, Nouredine Sidi ; Touhami, Hadj. / Home treatment of haemarthrosis with recombinant activated factor VII in patients with haemophilia A or B and inhibitors : experience from developing countries. In: Blood Coagulation and Fibrinolysis. 2016.
@article{7068350c34a842348e03909ed2e80368,
title = "Home treatment of haemarthrosis with recombinant activated factor VII in patients with haemophilia A or B and inhibitors: experience from developing countries",
abstract = "Home therapy for uncomplicated mild/moderate bleeding can decrease healthcare burden, promote self-esteem, reduce complications, and provide near-normal quality of life. To evaluate recombinant activated factor VII (rFVIIa) as home therapy for joint bleeds in Algeria, Morocco, Oman, Saudi Arabia, and United Arab Emirates. Twenty-seven patients aged more than 2 years with congenital haemophilia and inhibitors were monitored for up to 8 months after a first haemarthrosis episode treated with rFVIIa. Assessments were made by patients/caregivers with a standardized diary. The main measures included home-managed bleeds, haemostasis, and pain relief within 9?h after first injection. Additional analyses included convenience, time to pain resolution, and doses given within 48?h. Of 132 bleeds, 84 (63.6{\%}) were managed at home. Of these, successful haemostasis (partial or complete) was achieved at 9?h in 87.8{\%}, with pain relief for 84.0{\%}. For all treatment settings, successful haemostasis at 9?h was achieved for 86.3{\%} of bleeds, with pain relief achieved for 74.8{\%} of bleeds. Higher initial dosing was associated with fewer injections. Median time to complete haemostasis was 48?h (spontaneous bleeds) and 24?h (traumatic bleeds). Median time to complete pain relief was 24?h for both bleed types. Satisfaction with treatment was high. No safety concerns were reported. Results from this observational study agree with previous data on the safety and efficacy of home treatment with rFVIIa and will help to increase awareness and aggregate experience, fostering confidence in home management of haemophilia patients with inhibitors in developing countries.",
author = "Meriem Bensadok and Abdulkareem Almomen and Azzam Alzoebie and {el Fegoun}, {Soraya Benchikh} and Yasser Wali and Fati Hamzy and Mehalhal, {Nemra Gaid} and Fatiha Grifi and Selma Hamdi and Naima Mesli and Tarek Owaidah and Saad, {Hossam Ali} and Mansour, {Nouredine Sidi} and Hadj Touhami",
year = "2016",
month = "4",
day = "20",
doi = "10.1097/MBC.0000000000000564",
language = "English",
journal = "Blood Coagulation and Fibrinolysis",
issn = "0957-5235",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Home treatment of haemarthrosis with recombinant activated factor VII in patients with haemophilia A or B and inhibitors

T2 - experience from developing countries

AU - Bensadok, Meriem

AU - Almomen, Abdulkareem

AU - Alzoebie, Azzam

AU - el Fegoun, Soraya Benchikh

AU - Wali, Yasser

AU - Hamzy, Fati

AU - Mehalhal, Nemra Gaid

AU - Grifi, Fatiha

AU - Hamdi, Selma

AU - Mesli, Naima

AU - Owaidah, Tarek

AU - Saad, Hossam Ali

AU - Mansour, Nouredine Sidi

AU - Touhami, Hadj

PY - 2016/4/20

Y1 - 2016/4/20

N2 - Home therapy for uncomplicated mild/moderate bleeding can decrease healthcare burden, promote self-esteem, reduce complications, and provide near-normal quality of life. To evaluate recombinant activated factor VII (rFVIIa) as home therapy for joint bleeds in Algeria, Morocco, Oman, Saudi Arabia, and United Arab Emirates. Twenty-seven patients aged more than 2 years with congenital haemophilia and inhibitors were monitored for up to 8 months after a first haemarthrosis episode treated with rFVIIa. Assessments were made by patients/caregivers with a standardized diary. The main measures included home-managed bleeds, haemostasis, and pain relief within 9?h after first injection. Additional analyses included convenience, time to pain resolution, and doses given within 48?h. Of 132 bleeds, 84 (63.6%) were managed at home. Of these, successful haemostasis (partial or complete) was achieved at 9?h in 87.8%, with pain relief for 84.0%. For all treatment settings, successful haemostasis at 9?h was achieved for 86.3% of bleeds, with pain relief achieved for 74.8% of bleeds. Higher initial dosing was associated with fewer injections. Median time to complete haemostasis was 48?h (spontaneous bleeds) and 24?h (traumatic bleeds). Median time to complete pain relief was 24?h for both bleed types. Satisfaction with treatment was high. No safety concerns were reported. Results from this observational study agree with previous data on the safety and efficacy of home treatment with rFVIIa and will help to increase awareness and aggregate experience, fostering confidence in home management of haemophilia patients with inhibitors in developing countries.

AB - Home therapy for uncomplicated mild/moderate bleeding can decrease healthcare burden, promote self-esteem, reduce complications, and provide near-normal quality of life. To evaluate recombinant activated factor VII (rFVIIa) as home therapy for joint bleeds in Algeria, Morocco, Oman, Saudi Arabia, and United Arab Emirates. Twenty-seven patients aged more than 2 years with congenital haemophilia and inhibitors were monitored for up to 8 months after a first haemarthrosis episode treated with rFVIIa. Assessments were made by patients/caregivers with a standardized diary. The main measures included home-managed bleeds, haemostasis, and pain relief within 9?h after first injection. Additional analyses included convenience, time to pain resolution, and doses given within 48?h. Of 132 bleeds, 84 (63.6%) were managed at home. Of these, successful haemostasis (partial or complete) was achieved at 9?h in 87.8%, with pain relief for 84.0%. For all treatment settings, successful haemostasis at 9?h was achieved for 86.3% of bleeds, with pain relief achieved for 74.8% of bleeds. Higher initial dosing was associated with fewer injections. Median time to complete haemostasis was 48?h (spontaneous bleeds) and 24?h (traumatic bleeds). Median time to complete pain relief was 24?h for both bleed types. Satisfaction with treatment was high. No safety concerns were reported. Results from this observational study agree with previous data on the safety and efficacy of home treatment with rFVIIa and will help to increase awareness and aggregate experience, fostering confidence in home management of haemophilia patients with inhibitors in developing countries.

UR - http://www.scopus.com/inward/record.url?scp=84964326003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964326003&partnerID=8YFLogxK

U2 - 10.1097/MBC.0000000000000564

DO - 10.1097/MBC.0000000000000564

M3 - Article

C2 - 27100303

AN - SCOPUS:84964326003

JO - Blood Coagulation and Fibrinolysis

JF - Blood Coagulation and Fibrinolysis

SN - 0957-5235

ER -